NASDAQ · Biotechnology

Alpine Immune Sciences, Inc. (ALPN) Stock

$64.97 +0.02% NASDAQ: ALPN Healthcare

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies.

Valuation

MetricValue
Price$64.97
Market Cap$4.46B
P/E Ratio-101.52
P/B Ratio9.91
P/S Ratio75.70
EPS (TTM)$-0.64
52-Week High$65.00
52-Week Low$8.33
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-12.69%
ROA-8.47%
ROCE-13.10%
Gross Margin-37.41%
Operating Margin-75.16%
Net Margin-54.66%
Debt/Equity0.03
Current Ratio7.86

Annual Financials (USD)

Metric20192020202120222023
Revenue$2.0M$9.0M$23.0M$30.0M$59.0M
Operating Profit$-44.0M$-29.0M$-50.0M$-58.0M$-44.0M
Net Profit$-43.0M$-28.0M$-50.0M$-58.0M$-32.0M
EPS$-2.32$-1.34$-1.98$-1.73$-0.64
Op Margin-2504.3%-308.0%-212.7%-193.4%-75.2%

Balance Sheet (USD)

Metric20192020202120222023
Total Assets$54.0M$144.0M$256.0M$287.0M$380.0M
Total Liabilities$25.0M$82.0M$135.0M$107.0M$52.0M
Cash$16.0M$35.0M$68.0M$13.0M$44.0M
Borrowings$16.0M$23.0M$20.0M$14.0M$10.0M

Latest News

FDA approves first-of-its-kind cholesterol pill Lipfendra: What it will cost Yahoo Personal Finance · Jul 16, 2026 Wendy's is selling $1 Frostys. How, when to get one USA TODAY · Jul 16, 2026 How to budget on an irregular or unpredictable income Yahoo Personal Finance · Jul 16, 2026 Here's Why Investors Shouldn't Worry About Redwire's CEO Selling 25,369 Shares Motley Fool · Jul 16, 2026 Even Dan Jansen's Rivals Cheered When He Won The Gold Medal Investor's Business Daily · Jul 16, 2026

Cash Flow (USD)

Metric20192020202120222023
Operating Cash Flow$-35.0M$30.0M$-15.0M$-44.0M$-79.0M
Investing Cash Flow$16.0M$-74.0M$-53.0M$-114.0M$-111.0M
Financing Cash Flow$24.0M$61.0M$101.0M$103.0M$165.0M
Net Cash Flow$6.0M$19.0M$33.0M$-55.0M$31.0M
Free Cash Flow$-36.0M$29.0M$-15.0M$-44.0M$-79.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-1.28
EV / EBITDA-140.82
FCF Yield-1.78%
Quick Ratio7.87
Interest Coverage-451.53
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASPHFAscentage Pharma Group International $4.53 +0.00% -9.81 $1.69B 0.00%
CBAYCymaBay Therapeutics, Inc. $32.48 +0.03% -32.81 $3.73B 0.00%
CCXIChurchill Capital Corp XI $16.10 -3.10% 1548.08 $674.59M 0.00%
GBTGlobal Blood Therapeutics, Inc. $68.49 +0.01% -14.21 $0 0.00%
ISEEIVERIC bio, Inc. $39.95 +0.38% -27.55 $5.51B 0.00%

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.

Alpine Immune Sciences, Inc. is headquartered in US.

Alpine Immune Sciences, Inc. (ALPN) stock trades at $64.97 with a market capitalization of $4.46B. The stock is valued at a price-to-earnings (P/E) ratio of -101.52, price-to-book of 9.91, price-to-sales of 75.70. Over the past 52 weeks the stock has ranged between $8.33 and $65.00, and currently trades at its 52-week high.

On profitability, Alpine Immune Sciences, Inc. generates a return on equity (ROE) of -12.69%, return on capital employed of -13.10%, an operating margin of -75.16%, a net profit margin of -54.66%.

Official website: www.alpineimmunesciences.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides